Next-generation immune cell engagers for B cell depletion in autoimmune diseases www.nature.com/articles/s41... rdcu.be/NecnUNkptUFa This Review discusses the principles guiding the design of immune cell engagers and emerging stratgeies to improve safety and durability of response

Next-generation immune cell engagers for B cell depletion in autoimmune diseases - Nature Reviews Drug Discovery

Immune cell engagers are emerging as a strategy for deep B cell depletion in autoimmune diseases. This Review examines their mechanisms, clinical development and next-generation designs, including T c...

nature.com

For readers interested in the pipeline of drugs to treat chronic obstructive pulmonary disease (COPD), here's a comprehensive review www.nature.com/articles/s41... rdcu.be/BhP4KUSSns2a

Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities   - Nature Reviews Drug Discovery

Chronic obstructive pulmonary disease (COPD) is a progressive and severe respiratory disease featuring airway obstruction and recurrent exacerbations, driven by a complex network of inflammatory proce...

nature.com

COPD trial wins spur broad respiratory hopes nature.com/articles/d41... AstraZeneca’s tozorakimab reduced disease flare ups in patients with COPD, suggesting IL-33-targeted antibodies could offer broad potential in lung diseases. Read about the COPD pipeline in this news feature

The cellular landscape of druggable RNA-binding proteins nature.com/articles/s41... rdcu.be/Xdw8gA2w82Ea This new Perspective discusses opportunities to therapeutically target RNA-binding proteins, which are involved in the development of multiple diseases

The cellular landscape of druggable RNA-binding proteins - Nature Reviews Drug Discovery

RNA-binding proteins (RBPs) regulate every step of cellular RNA metabolism, and their dysregulation contributes to many diseases. This Perspective describes the endogenous and disease-linked roles of ...

nature.com

Refining therapeutic targeting of interleukin-6 by signalling mode selectivity nature.com/articles/s41... rdcu.be/4VH5Q2Uzx71a This new Review discusses how understanding of signalling mechanisms of the cytokine IL-6 could guide the discovery of safer and more effective drugs

Refining therapeutic targeting of interleukin-6 by signalling mode selectivity - Nature Reviews Drug Discovery

IL-6-targeted therapies have transformed the treatment of autoimmune diseases, but safety concerns related to the cytokine’s homeostatic functions remain. This Review examines classic and trans-signal...

nature.com

Our October issue is live! Read about mRNA therapeutics, orexin receptor agonists for narcolepsy, targeting T follicular helper cells, simulation-guided clinical trials and more here nature.com/nrd/volumes/...

The evolving landscape of drug targets www.nature.com/articles/s41... rdcu.be/22o1FPpNJ3Ga In the past 25 years, advances in areas such as genomics and the diversification of therapeutic modalities have expanded the drug target landscape. It now includes ~700 targets, as mapped in this new Review

Drugs that target myostatin signalling are among the most advanced in development to strengthen muscle for healthy ageing. Read about this and the other approaches being explored in this Review nature.com/articles/s41... rdcu.be/EVPsY9k2CTGa

Strengthening muscle for healthy ageing: innovative treatments for sarcopenia - Nature Reviews Drug Discovery

There are currently no approved therapies for sarcopenia, the age-related loss of skeletal muscle mass and strength. This Review discusses advances in understanding of the cellular, molecular and meta...

nature.com

First myostatin-targeted antibody approved for spinal muscular atrophy nature.com/articles/d41... Scholar Rock’s apitegromab has received FDA approval for SMA. Drug developers hope the drug class could be applied in other settings such as muscle preservation during weight loss

A translational framework for extrahepatic oligonucleotide delivery nature.com/articles/d41... This Comment article outlines an industry-grade quality framework to eliminate methodological artifacts and ensure the translational and commercial viability of novel oligonucleotide platforms

Upcoming FDA approval decisions in Q4 2026 www.nature.com/articles/d41... Notable potential approvals include a first-in-class B7H3-targeted ADC for small-cell lung cancer, an ASO for chronic hepatitis B infection and a PD1 x VEGF bispecific antibody for non-small-cell lung cancer

Upcoming FDA approval decisions in Q4 2026

Discover the world’s best science and medicine | Nature.com

nature.com

This Review in the September issue covers the clinical landscape for agonistic antibody-based immunotherapy for cancer and immune disorders, and mechanistic insights that could broaden its scope www.nature.com/articles/s41... rdcu.be/9y7jJZbHxe8a

Realizing the potential of agonistic antibody immunotherapy - Nature Reviews Drug Discovery

Agonistic antibodies initiate signalling by the receptors they target, mimicking the activities of native ligands. This Review discusses the clinical successes and failures of agonistic antibodies and...

nature.com

This Review in the September issue discusses targeting autophagy to limit malignant transformation, potentiate cancer cell death driven by existing drugs and restore immunosurveillance in support of immunotherapies www.nature.com/articles/s41... rdcu.be/MMNGMaj8ifwa

Autophagy modulation in cancer - Nature Reviews Drug Discovery

Autophagy has a highly complex and context-dependent role in cancer, challenging the development of autophagy-modulating strategies. This Review discusses the potential of targeting autophagy to count...

nature.com

Newest glue degrader nabs multiple myeloma approval www.nature.com/articles/d41... Iberdomide (Zenbexus; Bristol Myers Squibb) is an “important proof point” for targeted protein degradation, showing how new molecular glue degraders can improve on their predecessors

Newest glue degrader nabs multiple myeloma approval

Discover the world’s best science and medicine | Nature.com

nature.com

For readers interested in the potential of in vivo CAR-T cell therapies for cancer and autoimmune diseases, here's a comprehensive review by pioneers in the field rdcu.be/koc33UDidsza nature.com/articles/s41...

The landscape for in vivo CAR T cell therapies www.nature.com/articles/d41... This article analyses the pipeline of in vivo CAR-T therapies for cancer and autoimmune disorders, highlighting trends in delivery technologies, targets and indications.

The landscape for in vivo CAR T cell therapies

Discover the world’s best science and medicine | Nature.com

nature.com

🧠 Solute carrier membrane transporters are drug targets in the central nervous system & their therapeutic potential may extend much further. In Nature Reviews Drug Discovery, @supertifurgalab.bsky.social & Solgate explore new opportunities for #SLCs in CNS drug discovery. 🔗 bit.ly/4xiIFFd

Nature Reviews Drug Discovery@natrevdrugdiscov.nature.com · last mo.

Solute carrier membrane transporters: emerging targets in CNS disorders www.nature.com/articles/s41... rdcu.be/uQeAYKzFg8Ua This new Review discusses targeting SLC transporters in neurodegenerative diseases, autism spectrum disorders and epilepsy

This Review in the September issue discusses the evolving landscape of drugs targeting claudins in cancer, including monoclonal antibodies, CAR-T cell therapies, antibody-drug conjugates and bispecific antibodies www.nature.com/articles/s41... rdcu.be/vcwJ2mgqPs3a

Targeting claudins in cancer - Nature Reviews Drug Discovery

Claudins are emerging as clinically actionable targets in cancer, exemplified by the approval of CLDN-18.2-directed therapy. This review examines the biological basis and therapeutic exploitation of c...

nature.com

Strengthening muscle for healthy ageing: innovative treatments for sarcopenia www.nature.com/articles/s41... rdcu.be/NVL9v7ueUwAa This new Review discusses strategies targeting mitochondrial function, autophagy, anabolic signalling, vascularization, inflammageing and regeneration

Strengthening muscle for healthy ageing: innovative treatments for sarcopenia - Nature Reviews Drug Discovery

There are currently no approved therapies for sarcopenia, the age-related loss of skeletal muscle mass and strength. This Review discusses advances in understanding of the cellular, molecular and meta...

nature.com

Un-siloed biomedical opportunities www.nature.com/articles/d41... Edith Heard, CEO of the Francis Crick Institute in London @crick.ac.uk, discusses the need to break down biomedical boundaries

1/4 Delighted (+relieved) our @natrevdrugdiscov.nature.com perspective on AI in R&D finally out. Channeling R. Solow: why do we see AI everywhere in biopharma except in the productivity statistics? As we write, evidence of its clinically relevant impact remains “disappointingly limited.”

The FDA recently approved the first orexin receptor agonist for narcolepsy nature.com/articles/d41... Oveporexton is anticipated to transform the treatment of this sleep disorder, and potential additional applications have led to the class being dubbed the GLP-1s of neuroscience

For readers interested in the opportunities and pitfalls for CAR-T therapies for autoimmune diseases, here's a recent comprehensive Review www.nature.com/articles/s41... rdcu.be/97VgTv2SaRTa

Roads and detours for CAR T cell therapy in autoimmune diseases - Nature Reviews Drug Discovery

Following on from its success in eradicating malignant B cells in cancer, chimeric antigen receptor (CAR) T cell therapy has been extended to treat autoimmune diseases. This Review discusses the precl...

nature.com

Novartis and Bristol Myers Squibb have paused their CAR-T trials for #lupus and other autoimmune diseases to review safety concerns. CAR-T remains experimental, and continued research is needed to understand its benefits and risks. Read the announcement: buff.ly/QJBbN7L

Solute carrier membrane transporters: emerging targets in CNS disorders www.nature.com/articles/s41... rdcu.be/uQeAYKzFg8Ua This new Review discusses targeting SLC transporters in neurodegenerative diseases, autism spectrum disorders and epilepsy

For readers interested in JAK inhibitors for autoimmmune diseases, such as Roivant's brepocitinib that has just been approved by the FDA for dermatomyositis, here's a review on pharmacological targeting of the JAK-STAT pathway nature.com/articles/s41... rdcu.be/rpNrcuDMf4ha

The FDA has approved brepocitinib as a TYK2/JAK1 inhibitor from Roivant/Priovant Huge shout out to the #PfizerChemistry team who discovered the molecule - it was a large project team and when I joined the mol had already been identified and… #ChemSky 1/…

Our September issue is live! Read about brain-shuttle biologics, targeting claudins in cancer, agonist antibody-based immunotherapies, autophagy modulation in cancer and more here nature.com/nrd/volumes/...

Towards precision psychiatry: initial foundations and future directions www.nature.com/articles/s41... rdcu.be/fCeOU This new Perspective discusses how to align drug development with underlying neural dysfunctions using patient-specific measures of brain function such as EEG

Towards precision psychiatry: initial foundations and future directions - Nature Reviews Drug Discovery

Drug discovery for psychiatric disorders is a slow and challenging process, driven in part by reliance on symptom-based diagnostic criteria that fail to capture the underlying disease biology. In thei...

nature.com

For neurologists who want to stay current, Springer Nature has a new resource made for you. Nature Briefing: Clinical Neurology brings together key clinical developments and research from leading journals in the field in a weekly newsletter. Sign up is free go.springernature.com/int1/briefin...

Sign up for Nature Briefing: Clinical Neurology

go.springernature.com